PURPOSE To describe a multi-center preliminary experience of treating prosthetic above knee femoropopliteal (AKFP) bypass occlusion by placing a Viabahn stent graft inside the occluded prosthetic bypass graft. MATERIALS AND METHODS Retrospective analysis of consecutive 14 patients (mean age 73.2 ± 10.2, 78.6% male) receiving Viabahn stent graft inside the occluded prosthetic bypass graft for the treatment of prosthetic AKFP bypass occlusion in the collaborating hospitals from November 2016 to June 2019 was performed. RESULTS Technical success was achieved in all patients. Mean lesion length was 34.0 ± 3.5 cm, concomitant thrombectomy or thrombus aspiration was performed in 11 patients (78.6%), and average of 1.57 ± 0.65 Viabahn stent grafts were used. Mean ankle-brachial index improved from 0.24 ± 0.23 to 0.98 ± 0.14 after the treatment. All patients had preoperative ischemic symptoms with 9 patients (64.3%) having Rutherford class > 4 symptoms; however, all preoperative symptoms resolved after the treatment. During the mean follow-up of 450.9 ± 234.7 days, there were two target lesion revascularizations, leading to a primary patency rate of 92.9% and a secondary patency of 100.0% at 1 year. CONCLUSION Placing a Viabahn stent graft inside the occluded prosthetic bypass graft for the treatment of prosthetic AKFP bypass occlusion appears to be effective from our preliminary experience. Even though sample size is limited in our study, it may be considered as a potential treatment option before surgical reintervention.

中文翻译：

---

闭合假体旁路移植物内部Viabahn支架移植物治疗膝上F小腿旁路闭合症的初步经验。

目的描述通过将Viabahn支架植入物置于闭塞的假体旁路移植物内来治疗膝上股pop上（AKFP）假体的多中心初步经验。材料与方法自2016年11月至2019年6月，对合作医院中连续14例患者（平均年龄73.2±10.2，男性，占78.6％）接受Viabahn支架移植术进行回顾性分析，以治疗AKFP假体。结果所有患者均获得技术成功。平均病变长度为34.0±3.5 cm，11例患者（78.6％）同时进行了血栓切除术或血栓抽吸术，平均使用了1.57±0.65的Viabahn支架移植物。治疗后平均踝肱指数从0.24±0.23提高到0.98±0.14。所有患者均具有术前缺血症状，其中9例（64.3％）的卢瑟福级> 4种症状；所有患者均出现术前缺血症状。但是，所有术前症状在治疗后均得到缓解。在平均450.9±234.7天的随访期间，进行了两次目标病变血运重建，在1年时初次通畅率为92.9％，次要通畅率为100.0％。结论从我们的初步经验来看，将Viabahn支架植入物放置在封闭的假体旁路移植物内以治疗假体AKFP旁路阻塞是有效的。即使在我们的研究中样本量有限，在手术再次干预之前，也可以将其视为潜在的治疗选择。术前所有症状均得到缓解。在平均450.9±234.7天的随访期间，进行了两次目标病变血运重建，在1年时初次通畅率为92.9％，次要通畅率为100.0％。结论从我们的初步经验来看，将Viabahn支架植入物放置在封闭的假体旁路移植物内以治疗假体AKFP旁路阻塞是有效的。即使在我们的研究中样本量有限，在手术再次干预之前，也可以将其视为潜在的治疗选择。术前所有症状均得到缓解。在平均450.9±234.7天的随访期间，进行了两次目标病变血运重建，在1年时初次通畅率为92.9％，次要通畅率为100.0％。结论从我们的初步经验来看，将Viabahn支架植入物放置在封闭的假体旁路移植物内以治疗假体AKFP旁路阻塞是有效的。即使在我们的研究中样本量有限，在手术再次干预之前，也可以将其视为潜在的治疗选择。结论从我们的初步经验来看，将Viabahn支架植入物放置在封闭的假体旁路移植物内以治疗假体AKFP旁路阻塞是有效的。即使在我们的研究中样本量有限，在手术再次干预之前，也可以将其视为潜在的治疗选择。结论从我们的初步经验来看，将Viabahn支架植入物放置在封闭的假体旁路移植物内以治疗假体AKFP旁路阻塞是有效的。即使在我们的研究中样本量有限，在手术再次干预之前，也可将其视为潜在的治疗选择。